Short answer · Medically reviewed summary · Last updated: 2023-07-13
Arginase Deficiency/Argininemia is a rare autosomal recessive disorder that affects the urea cycle, a metabolic pathway responsible for removing ammonia from the body. This condition is caused by a deficiency of the enzyme arginase, which leads to the accumulation of toxic levels of arginine in the blood. The prevalence of Arginase Deficiency is estimated to be approximately 1 in 1,000,000 individuals worldwide.
What is the prevalence of Arginase Deficiency/Argininemia?
Prevalence of Arginase Deficiency/Argininemia: how many people are affected worldwide, differences by sex and region, with sources.
Arginase Deficiency/Argininemia is a rare autosomal recessive disorder that affects the urea cycle, a metabolic pathway responsible for removing ammonia from the body. This condition is caused by a deficiency of the enzyme arginase, which leads to the accumulation of toxic levels of arginine in the blood.
The prevalence of Arginase Deficiency is estimated to be approximately 1 in 1,000,000 individuals worldwide. It is considered one of the rarest urea cycle disorders. The condition has been reported in various ethnic groups, including individuals of European, African, and Asian descent.
Arginase Deficiency can present with a wide range of symptoms, including intellectual disability, developmental delay, seizures, spasticity, and growth retardation. The severity of the symptoms can vary widely among affected individuals.
Early diagnosis and treatment are crucial for managing Arginase Deficiency. Treatment typically involves a low-protein diet, arginine restriction, and the use of specific medications to manage symptoms and prevent complications.
Research and advancements in genetic testing have contributed to a better understanding of this rare disorder, allowing for improved diagnosis and management strategies.
